GALECTIN THERAPEUTICS INC
GALTNasdaq
$4.18
↓ -1.2%Jul 17 close · end-of-day
Price
1Y↑ +46.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$274.6M
Enterprise Value
$260.5M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$26.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
19.9%
ROIC
—
Debt / Equity
—
Net Cash
$14.1M
Return 1Y
+44.5%
Company profile
Galectin Therapeutics Inc. engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer. Belapectins is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis.
- CEO
- Joel Lewis
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9
- Headquarters
- Georgia
- Website
- galectintherapeutics.com
Management & directors
- Jamil KhurramChief Medical Officer
- Callicutt Jack WChief Financial Officer
- Lewis JoelPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
GALT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.08↓ -46.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$23.4M | -$30.2M | -$38.4M | -$38.1M | -$42.4M | -$20.1M |
| Net income | -$23.5M | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M |
| Diluted EPS | -$0.41 | -$0.52 | -$0.65 | -$0.74 | -$0.76 | -$0.48 |
| Operating cash flow | -$20.6M | -$24.3M | -$31.1M | -$33.0M | -$41.8M | -$23.9M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$11.3M | -$9.1M | -$12.4M | -$7.9M | -$4.6M | -$4.2M | -$3.4M | -$4.1M |
| Net income | -$12.4M | -$11.2M | -$12.0M | -$9.6M | -$7.5M | -$8.2M | -$5.5M | -$5.0M |
| Diluted EPS | -$0.20 | -$0.18 | -$0.19 | -$0.15 | -$0.12 | -$0.13 | -$0.08 | -$0.08 |
| Operating cash flow | -$8.3M | -$8.5M | -$12.8M | -$7.7M | -$6.6M | -$3.5M | -$6.0M | -$3.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 24, 2026
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | Jamil Khurram· Chief Medical Officer | Sale | 16,250 | $5.13 | $83,284.50 | filing |
| 2026-07-14 | Jamil Khurram· Chief Medical Officer | Option exercise | 16,250 | $3.04 | $49,400.00 | filing |
| 2026-06-29 | Jamil Khurram· Chief Medical Officer | Sale | 47,467 | $5.04 | $239,233.68 | filing |
| 2026-06-29 | Jamil Khurram· Chief Medical Officer | Option exercise | 47,467 | $2.50 | $118,667.50 | filing |
| 2026-06-29 | Shlevin Harold H. | Sale | 22,268 | $5.04 | $112,230.72 | filing |
| 2026-06-29 | Shlevin Harold H. | Option exercise | 22,268 | $1.23 | $27,389.64 | filing |
| 2026-06-26 | Shlevin Harold H. | Sale | 7,732 | $5.00 | $38,660.00 | filing |
| 2026-06-26 | Jamil Khurram· Chief Medical Officer | Sale | 2,533 | $5.00 | $12,665.00 | filing |
| 2026-06-26 | Jamil Khurram· Chief Medical Officer | Sale | 2,037 | $5.00 | $10,185.00 | filing |
| 2026-06-26 | Shlevin Harold H. | Option exercise | 7,732 | $1.23 | $9,510.36 | filing |
| 2026-06-26 | Jamil Khurram· Chief Medical Officer | Option exercise | 2,533 | $2.50 | $6,332.50 | filing |
| 2026-06-26 | Jamil Khurram· Chief Medical Officer | Option exercise | 2,037 | $2.20 | $4,481.40 | filing |
| 2026-06-23 | Jamil Khurram· Chief Medical Officer | Sale | 7,557 | $3.14 | $23,728.98 | filing |
| 2026-06-23 | Jamil Khurram· Chief Medical Officer | Option exercise | 7,557 | $1.23 | $9,295.11 | filing |
| 2026-05-26 | Jamil Khurram· Chief Medical Officer | Sale | 568 | $3.10 | $1,761.03 | filing |
| 2026-05-26 | Jamil Khurram· Chief Medical Officer | Option exercise | 568 | $1.23 | $698.64 | filing |
| 2026-02-06 | ELDRED KARY | Buy | 300 | $2.70 | $810.00 | filing |
| 2026-01-16 | Uihlein Richard E | Award | 13,158 | $3.04 | $40,000.32 | filing |
| 2026-01-06 | LEWIS JOEL· President and CEO | Sale | 37,698 | $3.58 | $134,853.29 | filing |
| 2026-01-06 | Jamil Khurram· Chief Medical Officer | Sale | 21,446 | $3.65 | $78,204.98 | filing |
| 2026-01-06 | CALLICUTT JACK W· Chief Financial Officer | Sale | 20,354 | $3.67 | $74,695.11 | filing |
| 2026-01-05 | LEWIS JOEL· President and CEO | ? | 56,332 | $3.88 | $218,568.16 | filing |
| 2026-01-05 | LEWIS JOEL· President and CEO | Sale | 27,731 | $3.91 | $108,342.24 | filing |
| 2026-01-05 | CALLICUTT JACK W· Chief Financial Officer | Sale | 25,732 | $3.90 | $100,298.19 | filing |
| 2026-01-05 | Jamil Khurram· Chief Medical Officer | Sale | 25,499 | $3.90 | $99,407.85 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.